<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr Metab (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Nutr Metab (Lond)</journal-id><journal-title-group><journal-title>Nutrition &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="epub">1743-7075</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6156864</article-id><article-id pub-id-type="publisher-id">297</article-id><article-id pub-id-type="doi">10.1186/s12986-018-0297-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daneshi-Maskooni</surname><given-names>Milad</given-names></name><address><email>mi-daneshi@razi.tums.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Keshavarz</surname><given-names>Seyed Ali</given-names></name><address><email>s_akeshavarz@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qorbani</surname><given-names>Mostafa</given-names></name><address><email>mqorbani1379@yahoo.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mansouri</surname><given-names>Siavash</given-names></name><address><email>siavash.mansouri@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Alavian</surname><given-names>Seyed Moayed</given-names></name><address><email>alavian@thc.ir</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Badri-Fariman</surname><given-names>Mahtab</given-names></name><address><email>mahtab.badri@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jazayeri-Tehrani</surname><given-names>Seyed Ali</given-names></name><address><email>ajazayeri@farabi.tums.ac.ir</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sotoudeh</surname><given-names>Gity</given-names></name><address><phone>09123906617</phone><email>gsotodeh@tums.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution>Department of Community Nutrition, School of Nutritional Sciences and Dietetics, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>No.44, Hojjatdoust Alley, Naderi Ave, Keshavarz Blvd, Tehran, 1416643931 Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution>Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution>Non-Communicable Diseases Research Center, </institution><institution>Alborz University of Medical Sciences, </institution></institution-wrap>Karaj, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0690 0331</institution-id><institution-id institution-id-type="GRID">grid.419140.9</institution-id><institution>Gastroenterohepatology Department, </institution><institution>National Iranian Oil Company (NIOC) Central Hospital, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9975 294X</institution-id><institution-id institution-id-type="GRID">grid.411521.2</institution-id><institution>Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), </institution><institution>Baqiyatallah University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>15</volume><elocation-id>63</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of metabolic syndrome. Despite the beneficial health effects of cardamom on dyslipidemia, hepatomegaly, and fasting hyperglycemia, no previous human study has been conducted on the efficacy of cardamom in NAFLD. The aim of this study was to assess the effects of green cardamom (GC) on serum Sirtuin-1 (Sirt1), inflammatory factors, and liver enzymes in overweight or obese NAFLD patients.</p></sec><sec><title>Methods</title><p id="Par2">The recruitment of subjects was conducted at the polyclinic of the central hospital of National Iranian Oil Company (NIOC), Tehran. Eighty-seven patients who participated were divided randomly into two groups according to the ultrasonography and eligibility criteria as cardamom (<italic>n</italic>&#x02009;=&#x02009;43) or placebo (<italic>n</italic>&#x02009;=&#x02009;44). The intervention involves taking two 500&#x000a0;mg capsules three times per day with meals for 3 months. General characteristics, dietary intake and physical activity status, weight and height were determined. In addition, serum Sirt1, tumor necrosis factor-alpha (TNF-&#x003b1;), high sensitive c-reactive protein (hs-CRP), interleukin-6 (IL-6), alanine transaminase (ALT), and aspartate transaminase (AST) were measured. The degree of fatty liver was determined at beginning and end of the study.</p></sec><sec><title>Results</title><p id="Par3">In comparison with placebo, GC significantly increased Sirt1 and decreased hs-CRP, TNF-&#x003b1;, IL-6, ALT, and the degree of fatty liver (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The differences in weight, BMI, and AST were not significant (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec><sec><title>Conclusion</title><p id="Par4">GC supplementation could improve some biomarkers related to fatty liver including inflammation, ALT, and Sirt1 in overweight/obese NAFLD patients. Further trials on cardamom&#x02019;s potential are suggested.</p></sec><sec><title>Trial registration</title><p id="Par5">Iranian Registry of Clinical Trials, <ext-link ext-link-type="uri" xlink:href="http://en.irct.ir/trial/15918">IRCT2015121317254N4</ext-link>. Registered 27/12/2015.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Non-alcoholic fatty liver disease</kwd><kwd>Green cardamom</kwd><kwd>Overweight or obesity</kwd><kwd>Sirtuin-1</kwd><kwd>Inflammatory factors</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004484</institution-id><institution>Tehran University of Medical Sciences and Health Services</institution></institution-wrap></funding-source><award-id>94-03-161-30123</award-id><principal-award-recipient><name><surname>Sotoudeh</surname><given-names>Gity</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par34">Non-alcoholic fatty liver disease (NAFLD), as a triglyceride accumulation of more than 5% in hepatocytes [<xref ref-type="bibr" rid="CR1">1</xref>], is emerging presently [<xref ref-type="bibr" rid="CR2">2</xref>]. The prevalence is 25.2% globally [<xref ref-type="bibr" rid="CR3">3</xref>], 65&#x02013;85% in obese and 15&#x02013;20% in non-obese adults [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], and between 20 and 40% in Iranian adults [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. NAFLD ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) and sometimes cirrhosis. Obesity, impaired blood glucose, hypertension, and hyperlipidemia as characteristics of metabolic syndrome [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], family history, age, severe weight loss, malnutrition, certain medicines or diseases [<xref ref-type="bibr" rid="CR10">10</xref>], and enteric microbiota [<xref ref-type="bibr" rid="CR11">11</xref>] are some risk factors of NAFLD. In simple words, NAFLD is the hepatic component of metabolic syndrome [<xref ref-type="bibr" rid="CR12">12</xref>]. The inflammatory cytokines, oxidative stress and subsequently insulin resistance may play a role in the pathology of this disease [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. There is a direct correlation between insulin resistance and liver fat content. The activators of nuclear factor &#x003ba;B (NF-&#x003ba;B) including TNF-&#x003b1;, increase the inflammatory cytokines that can subsequently impair insulin sensitivity [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par35">The silent information regulators proteins (sirtuins) have either mono-ADP-ribosyltransferase or deacylase activity, including deacetylase, desuccinylase, demalonylase, demyristoylase and depalmitoylase activity. Of the seven identified sirtuins &#x02013;Sirt1 to Sirt7&#x02013; in mammals, Sirt1 has been mostly studied. The activation of Sirt1 has different health benefits [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Sirt1 as a histone deacetylase-III in humans [<xref ref-type="bibr" rid="CR17">17</xref>], decreases oxidative stress by activating antioxidant enzymes including superoxide dismutase (SOD) and catalase [<xref ref-type="bibr" rid="CR18">18</xref>]. It plays important roles in insulin secretion, lipid/glucose/energy metabolism, insulin resistance, inflammatory process, cardiovascular, kidney, and NAFLD diseases [<xref ref-type="bibr" rid="CR19">19</xref>], mitochondrial and physiological function, and weight reduction [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Also, Sirt1 can increase PPAR-&#x003b3; coactivator-1 alpha (PGC-1&#x003b1;) that suppresses NF-&#x003ba;B [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. According to some evidence, Sirt1 is downregulated in the liver of NAFLD patients [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par36">The dietary polyphenols play important roles as anti-oxidant and anti-inflammatory compounds [<xref ref-type="bibr" rid="CR22">22</xref>]. GC as a spice contains multiple polyphenols including flavone (luteolin), flavonols (quercetin and kaempferol), and anthocyanidin (pelargonidin) [<xref ref-type="bibr" rid="CR23">23</xref>] that are NF-&#x003ba;B suppressors [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. The flavonoids and isoflavones (quercetin, resveratrol, and kaempferol) activate PGC-1&#x003b1; [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] and accordingly, GC may affect insulin sensitivity and hepatic steatosis by suppressing oxidative stress and inflammation [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par37">Lifestyle changes such as being physically active and losing weight gradually are the common treatment of NAFLD [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Because of the poorly characterized pathogenesis of NAFLD and the controversial treatment of it, new therapeutic plans may be effective for the prevention and treatment of NAFLD [<xref ref-type="bibr" rid="CR32">32</xref>]. The long-term keeping of weight loss is a challenge [<xref ref-type="bibr" rid="CR33">33</xref>], and so, the new approaches such as change of dietary components may be helpful [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. GC has some beneficial health effects including antihypertensive, antioxidant, fibrinolysis enhancement, gastroprotective, antispasmodic, antibacterial [<xref ref-type="bibr" rid="CR38">38</xref>], anti-inflammatory, anti-food toxins, anticarcinogenic, carminative, heart improvement, expectorant, diuretic [<xref ref-type="bibr" rid="CR39">39</xref>], and antiplatelet aggregation [<xref ref-type="bibr" rid="CR40">40</xref>]. The 1,8-cineole and alpha-terpinyl acetate are the most common agents of cardamom volatile oil. The reported effects for 1,8-cineole as the most extensively studied agent include the increase of apoptosis, the suppressing of prostaglandins, cytokines, nitric oxide, leukotrienes, interleukin-1 beta (IL-1&#x003b2;), TNF-&#x003b1;, inducible-nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), decrease of liver necrosis, vessels relaxation, the muscarinic receptors blocking, and anticholinergic effect [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par38">It was supposed that anti-inflammatory, antioxidant, hypolipidemic, and antibacterial effects of GC may improve NAFLD. Due to important and beneficial roles of Sirt1 in different metabolic pathways involved in the metabolic disorders especially fatty liver, many studies have assessed the activation of Sirt1 for effectively preventing the progress of the fatty liver disease [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The stimulating Sirt1 secretion in overweight or obese NAFLD patients by GC needs to be investigated. The levels of serum Sirt1 and the GC efficacy in overweight or obese NAFLD patients have not been previously studied. This trial was designed to assess the effect of GC on serum levels of Sirt1, inflammatory factors, and liver enzymes in overweight or obese NAFLD patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and subjects</title><p id="Par39">This study was designed as a double-blind randomized placebo-controlled clinical trial, approved by the ethics committee of Tehran University of Medical Sciences as IR.TUMS.REC.1394.791, and registered as IRCT2015121317254N4 on 27/12/2015. The participants were overweight or obese NAFLD patients referring to the sonography section of NIOC central hospital of Tehran. Our study lasted from 8 May 2016 until 17 September 2017.</p><p id="Par40"><italic>Inclusion criteria</italic> were having NAFLD by ultrasonography, 30&#x02013;60&#x000a0;years old and 25&#x02009;&#x02264;&#x02009;BMI&#x02009;&#x0003c;&#x02009;35&#x000a0;kg/m<sup>2</sup>. <italic>Exclusion criteria</italic> were history of alcohol usage during the past 12&#x000a0;months, inability to cooperate, conditions influencing the liver, secondary NAFLD, disability, uncontrolled hypertension (&#x0003e;&#x02009;140/90&#x000a0;mmHg), pregnancy or lactation, professional athlete, intake of ursodeoxycholic acid, antihypertensive, statins, probiotics, drugs interacting with cardamom, and antioxidant and multivitamin-mineral supplements during the past 3&#x000a0;months, weight loss for the past 3&#x000a0;months, and taking less than 90% of the study&#x02019;s supplements [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec4"><title>Randomization and intervention</title><p id="Par41">The block randomization method was used to divide patients into two groups, by an assistant (cardamom [<italic>n</italic>&#x02009;=&#x02009;43] or placebo [<italic>n</italic>&#x02009;=&#x02009;44]). The stratified randomization was used for controlling age (30&#x02013;45 and 46&#x02013;60&#x000a0;yrs) and gender. The ratio of groups was 1:1. After randomization and before the commencement of the study, 3 subjects from GC group and 2 subjects from placebo group declined to participate (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of the study participants</p></caption><graphic xlink:href="12986_2018_297_Fig1_HTML" id="MO1"/></fig></p><p id="Par42">Both the subjects and investigators were blinded to the intervention allocation. GC was supplied by Samex agency, India. The GC and placebo capsules were similar in shape, size, and color and were prepared by the <italic>Traditional Medicine Research Center (TMRC)</italic><bold>,</bold> Iran University of Medical Sciences, Tehran, Iran. The capsules contained 0.5&#x000a0;g of whole GC or toast flour. Before the intervention, the placebo capsules were placed near the cardamom capsules weekly to have their smell. This absorbed amount of cardamom volatile oil by the placebo capsules is very negligible to affect health parameters. The blinding of supplements for patients and investigators was done through packaging as A and B packs by TMRC. The dose of GC supplement was selected as 3&#x000a0;g/day [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] i.e. 2 capsules with each meal. Similarly, dose of the toast flour as placebo supplement was 3&#x000a0;g/day. The distribution of supplements was once a month and processes such as consumed capsules, potential complications, and the returned packages were checked monthly and by telephone weekly. The recommendations for lifestyle changes were given by an expert dietitian (MDM) placed in the hospital. The process of conducting the trial was checked by an assistant frequently and independently.</p><p id="Par43">The characteristic of GC was <italic>Elettaria cardamomum (L.) Maton, Family: Zingiberaceae, PMP-669</italic>. The whole GC was analyzed by The Institute of Medicinal Plants, Shahid Beheshti University of Medical Sciences, Tehran. The essential oil contents of GC by the gas chromatography-mass spectrometry (GC-MS) were 41% &#x003b1;-terpinyl acetate and 30% 1,8-cineole. The content of total phenolic acid by high-performance liquid chromatography (HPLC) based on standard gallic acid was 10.53&#x02009;&#x000b1;&#x02009;0.18&#x000a0;&#x003bc;g gallic acid equivalent/mg dry extract. Also, the content of total flavonoid by maceration method based on standard quercetin was 4.143&#x02009;&#x000b1;&#x02009;1.865&#x000a0;&#x003bc;g quercetin/mg dry extract.</p></sec><sec id="Sec5"><title>Assessments and measurements</title><sec id="Sec6"><title>General characteristics, dietary intakes, and physical activity</title><p id="Par44">After identifying NAFLD patients, the eligibility criteria were checked, the details and benefits of the study were clarified, and informed consent was obtained by the principal investigator. The general questionnaire, 24-h food recall (at the beginning, middle, and end), and short-form IPAQ (SF-IPAQ) questionnaire (at the beginning and end) were interviewly completed. The lifestyle recommendations [<xref ref-type="bibr" rid="CR34">34</xref>] which include 5% weight loss [<xref ref-type="bibr" rid="CR45">45</xref>] and increasing moderate-intensity aerobic physical activity at least 3 times/week for 30&#x02013;45&#x000a0;min [<xref ref-type="bibr" rid="CR46">46</xref>] were advised at the beginning. The lifestyle changes which include being physically active and losing weight gradually are the common treatment of NAFLD [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, the patients were advised to adopt these lifestyle changes to observe the medical ethics. These pieces of advice were equally presented to the all participants.</p><p id="Par45">The values from 24-h food recall (valid in Iran [<xref ref-type="bibr" rid="CR47">47</xref>]) were converted to gram per day [<xref ref-type="bibr" rid="CR48">48</xref>]. The dietary status was determined using the <italic>Nutritionist 4</italic> software [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par46">The levels of physical activity were low (&#x0003c;&#x02009;600 MET-minutes/week), moderate (600 to &#x0003c;&#x02009;1500 MET-minutes/week), and high (&#x02265;1500 MET-minutes/week) [<xref ref-type="bibr" rid="CR49">49</xref>]. The SF-IPAQ questionnaire had been validated in Iran [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec7"><title>Anthropometrics</title><p id="Par47">Weight (at the beginning and end) and height (at the beginning) were assessed using a digital scale and stadiometer (<italic>Seca&#x000ae; Germany, Model: 755 1,021,994</italic>). Body mass index (BMI) was calculated by dividing the weight in kilograms by squared height in meters.</p></sec><sec id="Sec8"><title>Sonography and serum factors</title><p id="Par48">At the beginning and end of the study, the ultrasonography of liver was done after 12&#x000a0;h fasting state, by just one radiologist to reduce human error differences.</p><p id="Par49">The 10&#x000a0;ml blood (at the beginning and end) collected from the peripheral vein after 12-h fasting during the night was centrifuged for 20&#x000a0;min (3000&#x000a0;<italic>g</italic>) and serum was frozen and stored at &#x02212;&#x02009;80&#x000a0;&#x000b0;C for analysis. The lab tasks (blood taking, storage, and tests) were done at the hospital.</p><p id="Par50">Serum IL-6, TNF-&#x003b1;, and Sirt1 were determined using the ELISA kits by <italic>Shanghai Crystal Day Biotech Co. Ltd&#x000ae;; Intra-assay CV&#x02009;&#x0003c;&#x02009;8%, Inter-assay CV&#x02009;&#x0003c;&#x02009;10</italic>% and sandwich ELISA by an automatic device (<italic>Elisys Uno Human&#x000ae;</italic>) [<xref ref-type="bibr" rid="CR52">52</xref>]. The sandwich ELISA by an automatic device (<italic>Elisys Uno Human&#x000ae;</italic>) for hs-CRP was done using ELISA kit by <italic>Diagnostics Biochem Canada (DBC) Inc&#x000ae;, REF: CAN-CRP-4360, Version 5.0; Intra-assay CV&#x02009;&#x02264;&#x02009;15.2%, Inter-assay CV&#x02009;&#x02264;&#x02009;9.9%</italic>. The serum levels of ALT and AST were measured using Hitachi analyzer device (<italic>q17&#x000ae;</italic>) and the specific kits as <italic>Bionik&#x000ae;, Liquid Stable, NADH. Kinetic UV.IFCC, Intra-assay CV&#x02009;&#x02264;&#x02009;4.27%, Inter-assay CV&#x02009;&#x02264;&#x02009;4.68% and Bionik&#x000ae;, Liquid Stable, NADH. Kinetic UV.Liquid, Intra-assay CV&#x02009;&#x02264;&#x02009;3.02%, Inter-assay CV&#x02009;&#x02264;&#x02009;3.00%</italic>, respectively.</p></sec></sec><sec id="Sec9"><title>The sample size</title><p id="Par51">The &#x0201c;two mean comparison formula&#x0201d; was used to calculate the sample size. In the previous study of the effects of cardamom on lipids, errors I and II, the mean difference of triglyceride (TG) between the groups, and the standard deviation of each group were 0.05 and 0.2, 5&#x000a0;mg/dl, and 8&#x000a0;mg/dl, respectively [<xref ref-type="bibr" rid="CR44">44</xref>]. In all, 46 subjects were considered for both groups (GC and placebo) with a prediction of 15% sample drop.</p></sec><sec id="Sec10"><title>Data analysis and accessibility</title><p id="Par52">The entry, security, coding, and storage of data were considered. The analysis was done by modified-intention to treat (m-ITT). The ITT population included all the randomized participants who received the allocated intervention. The missing data were imputed by using regression imputation method. The Kolmogorov-Smirnov test was used to determine normality of continuous variables. Chi-square, Fisher exact test, and t-test or Mann-Whitney test were used to assessed categorical and continuous baseline characteristics, respectively. Time effects and time &#x000d7; treatment interaction effects on all dependent variables were determined using two way repeated measures analysis of variance (TWRM-ANOVA). TWRM-ANOVA was adjusted for dietary intake of vitamin E and B6. The measurements were reported with 95% confidence interval (CI) and a <italic>P</italic>-value&#x0003c;&#x02009;0.05 was considered as statistically significant. The Statistical Package for Social Sciences, version 16 (SPSS Inc., Chicago, IL, USA) and STATA<sub>11SE</sub> (general-purpose statistical software package by StataCorp) software were used to analyze data. The access to the final dataset was possible only for the principal investigator and the results were given only by the publication.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Characteristics of patients</title><p id="Par53">According to the flowchart in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, a total of 787 people were screened (medical history). One hundred and fourteen patients met the eligibility criteria, of whom 15 declined and 7 couldn&#x02019;t participate. Ninety-two participants were randomized and 3 patients in GC group and 2 patients in the placebo group did not receive allocated intervention (refused to participate for personal reasons). Thus 87 participants completed the first visit (cardamom <italic>n</italic>&#x02009;=&#x02009;43; placebo <italic>n</italic>&#x02009;=&#x02009;44). Furthermore, 6 patients did not complete the study (for personal reasons and travelled; cardamom <italic>n</italic>&#x02009;=&#x02009;3; placebo <italic>n</italic>&#x02009;=&#x02009;3). In addition, the baseline values of blood biomarkers of one patient in the placebo group were not available. Finally, the data of 87 patients were analyzed according to the m-ITT.</p><p id="Par54">The general characteristics, physical activity level, and the degree of fatty liver of 87 overweight or obese NAFLD patients are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Patients had age and BMI of about 45&#x000a0;yrs. and 30&#x000a0;kg/m<sup>2</sup>, respectively and there were more numbers of male than female, married, employee or free job/retired, had nearly similar educations, in moderate and high economic levels, and low physical activity. The mean of supplement compliance by using capsule counting was more than 95% for both GC and placebo groups.<table-wrap id="Tab1"><label>Table 1</label><caption><p>General characteristics and physical activity level of overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Variables</th><th>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43) n(%) or Mean(SD)</th><th>Placebo (<italic>n</italic>&#x02009;=&#x02009;44) n(%) or Mean(SD)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="3">Age (yrs)</td><td>45.5(8.9)</td><td>45.0(7.7)</td><td char="." align="char">0.7<sup>*</sup></td></tr><tr><td rowspan="2">Gender</td><td colspan="2">Male</td><td>27(62.8)</td><td>27(61.4)</td><td char="." align="char" rowspan="2">0.8<sup>**</sup></td></tr><tr><td colspan="2">Female</td><td>16(37.2)</td><td>17(38.6)</td></tr><tr><td colspan="3">Height (cm)</td><td>166.9(10.3)</td><td>169.5(9.5)</td><td char="." align="char">0.3<sup>*</sup></td></tr><tr><td rowspan="2">Marriage status</td><td colspan="2">single</td><td>4(9.3)</td><td>7(15.9)</td><td char="." align="char" rowspan="2">0.3<sup>**</sup></td></tr><tr><td colspan="2">married</td><td>39(90.7)</td><td>37(84.1)</td></tr><tr><td rowspan="2">Job status</td><td colspan="2">employee, free job/retired</td><td>32(74.4)</td><td>30(68.2)</td><td char="." align="char" rowspan="2">0.5<sup>**</sup></td></tr><tr><td colspan="2">housewife, unemployed</td><td>11(25.6)</td><td>14(31.8)</td></tr><tr><td rowspan="2">Education level</td><td colspan="2">up to associate degree</td><td>18(41.9)</td><td>20(45.5)</td><td char="." align="char" rowspan="2">0.7<sup>**</sup></td></tr><tr><td colspan="2">Bachelor and higher</td><td>25(58.1)</td><td>24(54.5)</td></tr><tr><td rowspan="3">Economic level</td><td colspan="2">Low (&#x02264;3 living items)</td><td>0(0)</td><td>0(0)</td><td char="." align="char" rowspan="3">0.1<sup>**</sup></td></tr><tr><td colspan="2">moderate (4&#x02013;6 living items)</td><td>12(27.9)</td><td>6(13.6)</td></tr><tr><td colspan="2">High (&#x02265;7 living items)</td><td>31(72.1)</td><td>38(86.4)</td></tr><tr><td rowspan="3">Physical activity level (Baseline)</td><td colspan="2">low (&#x0003c;&#x02009;600 MET-minutes/week)</td><td>38(88.4)</td><td>34(77.3)</td><td char="." align="char" rowspan="3">0.1<sup>**</sup></td></tr><tr><td colspan="2">Moderate (600 to &#x0003c;&#x02009;1500 MET-minutes/week)</td><td>5(11.6)</td><td>10(22.7)</td></tr><tr><td colspan="2">High (&#x02265; 1500 MET-minutes/week)</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="3">Physical activity level (After 3&#x000a0;months)</td><td colspan="2">low (&#x0003c;&#x02009;600 MET-minutes/week)</td><td>29(67.4)</td><td>34(77.3)</td><td char="." align="char" rowspan="3">0.2<sup>$</sup></td></tr><tr><td colspan="2">Moderate (600 to &#x0003c;&#x02009;1500 MET-minutes/week)</td><td>12(27.9)</td><td>6(13.6)</td></tr><tr><td colspan="2">High (&#x02265; 1500 MET-minutes/week)</td><td>2(4.7)</td><td>4(9.1)</td></tr><tr><td char="&#x000d7;" align="char" rowspan="4">Fatty liver (Baseline)</td><td char="&#x000d7;" align="char" colspan="2">No</td><td>0(0)</td><td>0(0)</td><td char="." align="char" rowspan="4">0.1<sup>**</sup></td></tr><tr><td rowspan="3">Yes</td><td>Mild</td><td>27(62.8)</td><td>34(77.3)</td></tr><tr><td>Moderate</td><td>16(37.2)</td><td>10(22.7)</td></tr><tr><td>Severe</td><td>0(0)</td><td>0(0)</td></tr><tr><td char="&#x000d7;" align="char" rowspan="4">Fatty liver (After 3&#x000a0;months)</td><td char="&#x000d7;" align="char" colspan="2">No</td><td>18(41.8)</td><td>2(4.5)</td><td char="." align="char" rowspan="4">&#x0003c;&#x02009;0.001<sup>**</sup></td></tr><tr><td rowspan="3">Yes</td><td>Mild</td><td>22(51.2)</td><td>34(77.3)</td></tr><tr><td>Moderate</td><td>3(7.0)</td><td>8(18.2)</td></tr><tr><td>Severe</td><td>0(0)</td><td>0(0)</td></tr></tbody></table><table-wrap-foot><p><bold>*</bold>Mann-Whitney; <bold>**</bold>Chi-square; <bold>$</bold>Fisher exact test</p></table-wrap-foot></table-wrap></p><p id="Par55">Baseline characteristics were similar between patients, with the exception of the cardamom group that have higher dietary vitamin E intake (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of baseline mean for weight, BMI, Sirt1, inflammatory factors, and liver enzymes in overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43) Mean(SD)</th><th>Placebo (<italic>n</italic>&#x02009;=&#x02009;44) Mean(SD)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td>Weight (kg)</td><td>85.2(11.3)</td><td>88.6(13.2)</td><td>0.2<sup>*</sup></td></tr><tr><td>BMI (kg/m2)</td><td>30.5(2.4)</td><td>30.7(3.2)</td><td>0.6<sup>**</sup></td></tr><tr><td>Sirt1 (ng/ml)</td><td>1.3(0.5)</td><td>1.2(0.5)</td><td>0.6<sup>*</sup></td></tr><tr><td>TNF-&#x003b1; (ng/l)</td><td>16.7(4.6)</td><td>15.9(3.4)</td><td>0.3<sup>*</sup></td></tr><tr><td>IL-6 (ng/l)</td><td>9.7(3.0)</td><td>9.3(2.6)</td><td>0.5<sup>*</sup></td></tr><tr><td>hs-CRP (mg/l)</td><td>5.5(3.0)</td><td>5.4(3.2)</td><td>0.8<sup>**</sup></td></tr><tr><td>ALT (u/l)</td><td>44.5(16.4)</td><td>41.8(12.4)</td><td>0.4<sup>**</sup></td></tr><tr><td>AST (u/l)</td><td>26.0(9.3)</td><td>25.1(8.0)</td><td>0.7<sup>**</sup></td></tr></tbody></table><table-wrap-foot><p><bold>*</bold>t-test; <bold>**</bold>Mann-Whitney; <italic>BMI</italic> body mass index, <italic>Sirt1</italic> sirtuin-1, <italic>TNF-&#x003b1;</italic> tumor necrosis factor-alpha, <italic>IL-6</italic> interleukin-6, <italic>hs-CRP</italic> high sensitive c-reactive protein, <italic>ALT</italic> alanine transaminase, <italic>AST</italic> aspartate transaminase</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Dietary intakes of overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Dietary intakes</th><th>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43) Mean(SD)</th><th>Placebo (<italic>n</italic>&#x02009;=&#x02009;44) Mean(SD)</th><th colspan="2"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="3">Energy (kcal)</td><td>Baseline</td><td>2309.3(763.3)</td><td>2164.6(761.6)</td><td>0.3<sup>*</sup></td><td char="." align="char" rowspan="3">0.4<sup>**</sup></td></tr><tr><td>1.5&#x000a0;Months</td><td>1857.8(563.7)</td><td>1871.1(641.1)</td><td>0.9</td></tr><tr><td>3&#x000a0;Months</td><td>1947.5(656.7)</td><td>1978.4(636.8)</td><td>0.8</td></tr><tr><td rowspan="3">Protein (g)</td><td>Baseline</td><td>91.3(37.8)</td><td>83.7(34.4)</td><td>0.3</td><td char="." align="char" rowspan="3">0.3</td></tr><tr><td>1.5&#x000a0;Months</td><td>77.1(34.1)</td><td>74.8(31.6)</td><td>0.7</td></tr><tr><td>3&#x000a0;Months</td><td>79.6(31.7)</td><td>83.1(30.4)</td><td>0.7</td></tr><tr><td rowspan="3">Protein (%)</td><td>Baseline</td><td>15.8(4.2)</td><td>15.5(4.1)</td><td>0.7</td><td char="." align="char" rowspan="3">0.6</td></tr><tr><td>1.5&#x000a0;Months</td><td>16.2(3.7)</td><td>15.9(3.7)</td><td>0.6</td></tr><tr><td>3&#x000a0;Months</td><td>16.4(4.4)</td><td>16.9(3.5)</td><td>0.5</td></tr><tr><td rowspan="3">Carbohydrate (g)</td><td>Baseline</td><td>275.3(110.7)</td><td>261.1(94.0)</td><td>0.5</td><td char="." align="char" rowspan="3">0.3</td></tr><tr><td>1.5&#x000a0;Months</td><td>221.6(76.4)</td><td>234.6(80.6)</td><td>0.6</td></tr><tr><td>3&#x000a0;Months</td><td>231.1(90.3)</td><td>239.5(81.1)</td><td>0.6</td></tr><tr><td rowspan="3">Carbohydrate (%)</td><td>Baseline</td><td>47.5(10.3)</td><td>48.7(9.8)</td><td>0.5</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>47.8(8.1)</td><td>50.5(6.6)</td><td>0.08</td></tr><tr><td>3&#x000a0;Months</td><td>47.3(7.8)</td><td>48.6(7.1)</td><td>0.4</td></tr><tr><td rowspan="3">Fat (g)</td><td>Baseline</td><td>99.2(36.9)</td><td>89.9(43.9)</td><td>0.2</td><td char="." align="char" rowspan="3">0.5</td></tr><tr><td>1.5&#x000a0;Months</td><td>78.0(26.6)</td><td>75.1(30.6)</td><td>0.3</td></tr><tr><td>3&#x000a0;Months</td><td>82.3(29.6)</td><td>81.4(34.2)</td><td>0.5</td></tr><tr><td rowspan="3">Fat (%)</td><td>Baseline</td><td>38.7(8.6)</td><td>37.2(8.4)</td><td>0.4</td><td char="." align="char" rowspan="3">0.8</td></tr><tr><td>1.5&#x000a0;Months</td><td>38.0(6.7)</td><td>35.8(5.2)</td><td>0.1</td></tr><tr><td>3&#x000a0;Months</td><td>38.2(6.3)</td><td>36.8(6.8)</td><td>0.3</td></tr><tr><td rowspan="3">Cholesterol (mg)</td><td>Baseline</td><td>234.4(143.5)</td><td>221.9(174.5)</td><td>0.3</td><td char="." align="char" rowspan="3">0.8</td></tr><tr><td>1.5&#x000a0;Months</td><td>208.0(134.4)</td><td>186.1(141.6)</td><td>0.3</td></tr><tr><td>3&#x000a0;Months</td><td>290.6(375.1)</td><td>255.3(154.9)</td><td>0.4</td></tr><tr><td rowspan="3">Saturated fat (g)</td><td>Baseline</td><td>26.0(11.2)</td><td>24.0(13.7)</td><td>0.4</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>21.2(9.6)</td><td>21.2(11.7)</td><td>0.7</td></tr><tr><td>3&#x000a0;Months</td><td>23.8(11.3)</td><td>22.8(8.7)</td><td>0.8</td></tr><tr><td rowspan="3">Monounsaturated fatty acid (g)</td><td>Baseline</td><td>36.2(14.3)</td><td>32.9(16.9)</td><td>0.1</td><td char="." align="char" rowspan="3">0.6</td></tr><tr><td>1.5&#x000a0;Months</td><td>28.3(10.0)</td><td>27.5(11.4)</td><td>0.5</td></tr><tr><td>3&#x000a0;Months</td><td>30.5(11.2)</td><td>29.1(11.0)</td><td>0.3</td></tr><tr><td rowspan="3">Polyunsaturated fatty acid (g)</td><td>Baseline</td><td>26.3(13.1)</td><td>22.4(12.2)</td><td>0.08</td><td char="." align="char" rowspan="3">0.1</td></tr><tr><td>1.5&#x000a0;Months</td><td>20.2(9.2)</td><td>19.5(8.8)</td><td>0.5</td></tr><tr><td>3&#x000a0;Months</td><td>19.2(8.6)</td><td>20.1(12.1)</td><td>0.7</td></tr><tr><td rowspan="3">Vitamin A (RAE) (&#x003bc;g)</td><td>Baseline</td><td>465.7(449.5)</td><td>419.1(434.7)</td><td>0.4</td><td char="." align="char" rowspan="3">0.3</td></tr><tr><td>1.5&#x000a0;Months</td><td>285.1(222.8)</td><td>375.5(326.9)</td><td>0.2</td></tr><tr><td>3&#x000a0;Months</td><td>365.5(349.3)</td><td>397.2(246.2)</td><td>0.1</td></tr><tr><td rowspan="3">Carotenoids (mg)</td><td>Baseline</td><td>10.3(9.3)</td><td>8.7(8.2)</td><td>0.3</td><td char="." align="char" rowspan="3">0.2</td></tr><tr><td>1.5&#x000a0;Months</td><td>6.9(6.7)</td><td>6.9(7.3)</td><td>0.8</td></tr><tr><td>3&#x000a0;Months</td><td>7.2(7.5)</td><td>8.9(6.3)</td><td>0.08</td></tr><tr><td rowspan="3">Vitamin C (mg)</td><td>Baseline</td><td>88.7(92.1)</td><td>93.2(84.0)</td><td>0.7</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>84.6(83.4)</td><td>79.1(60.2)</td><td>0.8</td></tr><tr><td>3&#x000a0;Months</td><td>76.0(52.0)</td><td>87.1(61.9)</td><td>0.4</td></tr><tr><td rowspan="3">Calcium (mg)</td><td>Baseline</td><td>968.3(589.4)</td><td>872.0(530.4)</td><td>0.3</td><td char="." align="char" rowspan="3">0.05</td></tr><tr><td>1.5&#x000a0;Months</td><td>925.4(390.3)</td><td>951.3(490.1)</td><td>0.7</td></tr><tr><td>3&#x000a0;Months</td><td>930.5(485.1)</td><td>1145.1(533.4)</td><td>0.03</td></tr><tr><td rowspan="3">Iron (mg)</td><td>Baseline</td><td>15.1(6.6)</td><td>14.0(4.7)</td><td>0.4</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>11.6(4.0)</td><td>11.5(3.8)</td><td>0.8</td></tr><tr><td>3&#x000a0;Months</td><td>12.3(5.0)</td><td>11.7(4.4)</td><td>0.5</td></tr><tr><td rowspan="3">Vitamin D (&#x003bc;g)</td><td>Baseline</td><td>0.9(1.4)</td><td>1.5(3.0)</td><td>0.7</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>0.9(1.5)</td><td>1.6(2.4)</td><td>0.1</td></tr><tr><td>3&#x000a0;Months</td><td>1.2(1.2)</td><td>2.1(2.1)</td><td>0.03</td></tr><tr><td rowspan="3">Vitamin E (mg)</td><td>Baseline</td><td>31.7(16.2)</td><td>24.3(12.7)</td><td>0.01</td><td char="." align="char" rowspan="3">0.01</td></tr><tr><td>1.5&#x000a0;Months</td><td>23.8(11.2)</td><td>22.3(9.7)</td><td>0.4</td></tr><tr><td>3&#x000a0;Months</td><td>22.6(10.3)</td><td>23.8(11.3)</td><td>0.8</td></tr><tr><td rowspan="3">Vitamin B1 (mg)</td><td>Baseline</td><td>1.6(0.7)</td><td>1.6(0.6)</td><td>0.6</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>1.4(0.5)</td><td>1.4(0.5)</td><td>0.9</td></tr><tr><td>3&#x000a0;Months</td><td>1.5(0.5)</td><td>1.5(0.5)</td><td>0.6</td></tr><tr><td rowspan="3">Vitamin B2 (mg)</td><td>Baseline</td><td>1.9(1.0)</td><td>1.7(0.8)</td><td>0.6</td><td char="." align="char" rowspan="3">0.06</td></tr><tr><td>1.5&#x000a0;Months</td><td>1.6(0.6)</td><td>1.6(0.7)</td><td>0.9</td></tr><tr><td>3&#x000a0;Months</td><td>1.6(0.7)</td><td>2.0(0.8)</td><td>0.07</td></tr><tr><td rowspan="3">Vitamin B3 (mg)</td><td>Baseline</td><td>27.0(13.5)</td><td>23.9(12.7)</td><td>0.2</td><td char="." align="char" rowspan="3">0.4</td></tr><tr><td>1.5&#x000a0;Months</td><td>21.8(12.9)</td><td>19.9(11.5)</td><td>0.4</td></tr><tr><td>3&#x000a0;Months</td><td>21.1(8.2)</td><td>21.9(10.3)</td><td>0.8</td></tr><tr><td rowspan="3">Vitamin B6 (mg)</td><td>Baseline</td><td>1.9(0.9)</td><td>1.7(0.7)</td><td>0.2</td><td char="." align="char" rowspan="3">0.02</td></tr><tr><td>1.5&#x000a0;Months</td><td>1.6(0.7)</td><td>1.5(0.7)</td><td>0.4</td></tr><tr><td>3&#x000a0;Months</td><td>1.5(0.5)</td><td>1.7(0.6)</td><td>0.1</td></tr><tr><td rowspan="3">Folate (DFE) (&#x003bc;g)</td><td>Baseline</td><td>405.7(192.2)</td><td>457.2(182.8)</td><td>0.8</td><td char="." align="char" rowspan="3">0.5</td></tr><tr><td>1.5&#x000a0;Months</td><td>370.8(176.5)</td><td>363.7(157.1)</td><td>0.6</td></tr><tr><td>3&#x000a0;Months</td><td>388.0(183.1)</td><td>348.8(130.9)</td><td>0.2</td></tr><tr><td rowspan="3">Vitamin B12 (&#x003bc;g)</td><td>Baseline</td><td>4.1(2.5)</td><td>4.1(2.8)</td><td>0.8</td><td char="." align="char" rowspan="3">0.9</td></tr><tr><td>1.5&#x000a0;Months</td><td>3.5(2.1)</td><td>3.6(2.5)</td><td>0.9</td></tr><tr><td>3&#x000a0;Months</td><td>4.6(3.8)</td><td>4.4(2.0)</td><td>0.5</td></tr><tr><td rowspan="3">Vitamin K (&#x003bc;g)</td><td>Baseline</td><td>257.3(489.8)</td><td>198.3(371.0)</td><td>0.5</td><td char="." align="char" rowspan="3">0.4</td></tr><tr><td>1.5&#x000a0;Months</td><td>118.9(225.8)</td><td>147.9(233.4)</td><td>0.2</td></tr><tr><td>3&#x000a0;Months</td><td>195.0(373.0)</td><td>113.2(193.2)</td><td>0.8</td></tr><tr><td rowspan="3">Zinc (mg)</td><td>Baseline</td><td>11.8(5.2)</td><td>11.5(4.8)</td><td>0.9</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>9.7(3.6)</td><td>10.4(4.1)</td><td>0.5</td></tr><tr><td>3&#x000a0;Months</td><td>11.5(6.2)</td><td>11.4(3.8)</td><td>0.6</td></tr><tr><td rowspan="3">Selenium (&#x003bc;g)</td><td>Baseline</td><td>98.9(48.1)</td><td>106.9(52.4)</td><td>0.4</td><td char="." align="char" rowspan="3">0.7</td></tr><tr><td>1.5&#x000a0;Months</td><td>85.6(42.3)</td><td>94.1(38.7)</td><td>0.3</td></tr><tr><td>3&#x000a0;Months</td><td>101.4(50.7)</td><td>103.3(43.5)</td><td>0.7</td></tr><tr><td rowspan="3">Total fiber (g)</td><td>Baseline</td><td>30.3(16.5)</td><td>26.6(15.3)</td><td>0.2</td><td char="." align="char" rowspan="3">0.3</td></tr><tr><td>1.5&#x000a0;Months</td><td>26.1(13.1)</td><td>22.4(10.2)</td><td>0.1</td></tr><tr><td>3&#x000a0;Months</td><td>24.7(12.7)</td><td>25.2(12.2)</td><td>0.6</td></tr></tbody></table><table-wrap-foot><p>*Total of the column: t-test or Mann-Whitney; **Total of the column: Two way repeated measures-ANOVA (TWRM-ANOVA)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Changes in dietary intakes, degree of fatty liver, and blood biomarkers</title><p id="Par56">The dietary intakes during the study were almost similar between groups, except for significantly higher dietary intake of vitamins E and B6 in the cardamom group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) which were considered as confounders in the final analysis. Within cardamom group, the mean difference of AST was not significant (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), whereas the weight, BMI, ALT, IL-6, TNF-&#x003b1;, and hs-CRP decreased and Sirt1 increased significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Within placebo group, the mean difference of weight, BMI, hs-CRP, ALT, and AST were not significant (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), but the IL-6 and TNF-&#x003b1; decreased and Sirt1 increased significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). At the end, compared to placebo, cardamom significantly improved fatty liver.</p><p id="Par57">According to the time-by-treatment interaction effect in both unadjusted and adjusted analysis model, ALT, IL-6, TNF-&#x003b1;, and hs-CRP decreased and Sirt1 increased significantly among cardamom group in comparison with the placebo group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The time-by-treatment interaction effect had trend for weight (<italic>P</italic>&#x02009;=&#x02009;0.051) and BMI (<italic>P</italic>&#x02009;=&#x02009;0.06) in the unadjusted model due to a small but non-significant decrease in the cardamom group more than the placebo group (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>The changes of weight, BMI, Sirt1, inflammatory factors, and liver enzymes in overweight/obese NAFLD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">Intervention</th><th rowspan="2">Baseline Mean(SD)</th><th rowspan="2">3&#x000a0;Months Mean(SD)</th><th rowspan="2"><italic>P</italic>-value<sup>$</sup></th><th rowspan="2">Mean Difference (95% CI)</th><th colspan="3"><italic>P</italic>-value<sup>#</sup></th></tr><tr><th>Time</th><th>Treatment</th><th>Interaction</th></tr></thead><tbody><tr><td rowspan="2">Weight (kg)</td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>85.2(11.3)</td><td>84.2(11.3)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;1.0 (&#x02212;1.7, &#x02212;0.2)</td><td>&#x0003c;&#x02009;0.001</td><td>0.1</td><td>0.051</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>88.6(13.2)</td><td>88.2(13.9)</td><td>0.2</td><td>&#x02212;0.4 (&#x02212;1.27, 0.47)</td><td>0.001</td><td>0.1</td><td>0.2</td></tr><tr><td rowspan="2">BMI (kg/m<sup>2</sup>)<sup>*</sup></td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>30.5(2.4)</td><td>30.1(2.4)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;0.4 (&#x02212;0.55, &#x02212;0.24)</td><td>&#x0003c;&#x02009;0.001</td><td>0.8</td><td>0.06</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>30.7(3.2)</td><td>30.6(3.4)</td><td>0.1</td><td>&#x02212;0.1 (&#x02212;&#x02009;0.31, 0.11)</td><td>&#x0003c;&#x02009;0.001</td><td>0.8</td><td>0.2</td></tr><tr><td rowspan="2">Sirt1 (ng/ml)<sup>**</sup></td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>1.3(0.5)</td><td>1.7(0.5)</td><td>&#x0003c;&#x02009;0.001</td><td>0.4 (0.36, 0.43)</td><td>&#x0003c;&#x02009;0.001</td><td>0.054</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>1.2(0.5)</td><td>1.3(0.5)</td><td>0.003</td><td>0.1 (0.06, 0.13)</td><td>&#x0003c;&#x02009;0.001</td><td>0.04</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="2">TNF-&#x003b1; (ng/l)</td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>16.7(4.6)</td><td>8.7(4.3)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;8.0 (&#x02212;8.2, &#x02212;7.7)</td><td>&#x0003c;&#x02009;0.001</td><td>0.001</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>15.9(3.4)</td><td>15.2(3.7)</td><td>0.03</td><td>&#x02212;0.7 (&#x02212;0.9, &#x02212;0.4)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="2">IL-6 (ng/l)</td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>9.7(3.0)</td><td>5.0(2.6)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;4.7 (&#x02212;4.8, &#x02212;4.5)</td><td>&#x0003c;&#x02009;0.001</td><td>0.008</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>9.3(2.6)</td><td>8.4(2.5)</td><td>0.001</td><td>&#x02212;0.9 (&#x02212;1.0, &#x02212;&#x02009;0.7)</td><td>&#x0003c;&#x02009;0.001</td><td>0.009</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="2">hs-CRP (mg/l)^</td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>5.5(3.0)</td><td>3.7(2.0)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;1.8 (&#x02212;&#x02009;1.9, &#x02212;&#x02009;1.6)</td><td>&#x0003c;&#x02009;0.001</td><td>0.3</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>5.4(3.2)</td><td>5.3(3.0)</td><td>0.08</td><td>&#x02212;0.1 (&#x02212;0.3, 0.1)</td><td>0.01</td><td>0.4</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="2">ALT (u/l)<sup>**</sup></td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>44.5(16.4)</td><td>31.8(12.0)</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02212;12.7 (&#x02212;13.6, &#x02212;&#x02009;11.7)</td><td>&#x0003c;&#x02009;0.001</td><td>0.1</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>41.8(12.4)</td><td>41.3(12.9)</td><td>0.5</td><td>&#x02212;0.5 (&#x02212;1.3, 0.3)</td><td>0.006</td><td>0.1</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td rowspan="2">AST (u/l)^</td><td>Cardamom (<italic>n</italic>&#x02009;=&#x02009;43)</td><td>26.0(9.3)</td><td>25.0(8.8)</td><td>0.08</td><td>&#x02212;1.0 (&#x02212;1.6, &#x02212;0.4)</td><td>0.2</td><td>0.9</td><td>0.1</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;44)</td><td>25.1(8.0)</td><td>25.2(7.6)</td><td>0.8</td><td>0.1 (&#x02212;0.4, 0.6)</td><td>0.01</td><td>0.7</td><td>0.3</td></tr></tbody></table><table-wrap-foot><p><bold>*</bold>Inversely transformed; <bold>**</bold>Transformed by square root; <bold>^</bold>Logarithmically transformed; <bold>$</bold>Paired t-test; <bold>#</bold>Two way repeated measures-ANOVA (TWRM-ANOVA), top row: unadjusted; bottom row: adjusted for vitamins E and B6 intake; <italic>BMI</italic> body mass index, <italic>Sirt1</italic> sirtuin-1, <italic>TNF-&#x003b1;</italic> tumor necrosis factor-alpha, <italic>IL-6</italic> interleukin-6, <italic>hs-CRP</italic> high sensitive c-reactive protein, <italic>ALT</italic> alanine transaminase, <italic>AST</italic> aspartate transaminase</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Safety</title><p id="Par58">The patients reported no side effects associated with the treatment. Only one patient in the placebo group reported nausea and constipation in one of his follow up.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par59">This trial for the first time assessed the effects of GC on blood inflammatory biomarkers, liver enzymes, and Sirt1 in overweight/obese NAFLD patients. According to time-by-treatment interaction effect in both unadjusted and adjusted analysis model, ALT, IL-6, TNF-&#x003b1;, and hs-CRP decreased and Sirt1 increased significantly among cardamom group in comparison with the placebo group. Moreover, the improvements in the degree of fatty liver in cardamom group was significantly higher than the placebo group. The decrease of the weight and BMI in cardamom group had a trend in comparison with the placebo group in unadjusted analysis model.</p><p id="Par60">The results of different studies on the effects of cardamom or polyphenol-rich foods showed some controversies and some of them are presented as follows.</p><p id="Par61">The polyphenols, especially resveratrol, are activators of Sirt1 [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>] and they can improve obesity [<xref ref-type="bibr" rid="CR55">55</xref>]. In our study, cardamom increased the serum Sirt1 significantly; however, the decrease of weight and BMI were not significant. The reasons are likely short duration and lower sample size of the study. Furthermore, in an experimental study on streptozotocin-induced diabetic rats, treatment with low-, intermediate-, or high-polyphenol cocoa for 16&#x000a0;weeks (i.e., 0.12, 2.9 or 22.9&#x000a0;mg/kg/day of polyphenols) improved Sirt1 activity [<xref ref-type="bibr" rid="CR56">56</xref>]. Sirts, particularly Sirt1, deacylate histones/proteins and have a number of activities including anti-inflammatory activity that may prevent and reduce the complications, development, and progression of NAFLD [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par62">Serum level of Sirt1 was measured in this study. Sirt1 was primarily represented as a nuclear protein [<xref ref-type="bibr" rid="CR57">57</xref>] and leukocytes (peripheral blood mononuclear cell [PBMC]) have been used for determining Sirt1 expression [<xref ref-type="bibr" rid="CR58">58</xref>]. However, it was demonstrated that Sirt1 moves between the nucleus and cytoplasm. Sirt1 has been recently determined in the serum, in spite of the fact that its exact origin is unclear [<xref ref-type="bibr" rid="CR57">57</xref>]. Serum Sirt1 has been reported as a potential biomarker for some diseases such as aging-associated diseases [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par63">In two separate animal studies, cardamom significantly decreased weight gain and serum AST and ALT levels [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. In line with this study, the cardamom in diabetic patients for 8&#x000a0;weeks have no significant effects on measures of weight, BMI, waist, and hs-CRP [<xref ref-type="bibr" rid="CR61">61</xref>]. This may be attributed to the type and form of the supplementation and the duration of the intervention.</p><p id="Par64">Two cellular studies on cardamom demonstrated the suppression and inhibition of IL-6 and TNF-&#x003b1; release [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. The beneficial effects of cardamom on inflammatory factors including IL-6, TNF-&#x003b1;, and NF-&#x003ba;B [<xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref>] and serum AST and ALT levels [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>] had been observed in most of the animal models.</p><p id="Par65">Cardamom supplementation in hyperlipidemic, overweight, and obese pre-diabetic women for 8&#x000a0;weeks decreased serum hs-CRP level after adjustment of some covariates [<xref ref-type="bibr" rid="CR72">72</xref>]. Another human study on the effects of daily consumption of Arabic coffee with two different doses of cardamom did not show significant alteration in the concentration of ALT, AST, and C-reactive protein (CRP). This could be attributed to the fact that participants were healthy subjects who had normal levels of CRP, and no indications of inflammation [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par66">Cardamom&#x02019;s bioactive principles (i.e. 1,8-cineol [eucalyptol], beta-pinene, geraniol) had been revealed to have anti-inflammatory activity by binding to TNF-&#x003b1;, IL-1 beta, IL-4, and IL-5 [<xref ref-type="bibr" rid="CR74">74</xref>]. In addition, clinical trial reviews of natural products including ginger, turmeric, and other polyphenol-rich compounds [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>] and most studies on polyphenolic compounds have showed decreased levels of inflammatory factors including IL-6, TNF-&#x003b1;, and hs-CRP in healthy or non-healthy subjects [<xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par67">The reasons why our results were in accordance or contrary to other studies can be attributed to the difference in the type and design of the study, the sample size, the type of disease, the type and form of supplementation, the intervention duration, and the higher or lower values of the serum profiles at the beginning of the study.</p><p id="Par68">The reported mechanisms for beneficial effects of GC on inflammation include decreased infiltration of inflammatory cells, lipid peroxidation, and levels of advanced oxidation protein products (AOPP), increase of antioxidant enzymes activity [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], inhibition of inflammatory mediators including COX-2, iNOS, and NF-&#x003ba;B [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>], decrease of hemolysis by the vitamin E deficiency [<xref ref-type="bibr" rid="CR89">89</xref>], and increase of PPAR&#x003b3; activity and cytotoxicity of natural killer cells [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par69">The explained mechanisms in the improvement of the liver enzymes and the degree of fatty liver by cardamom include decrease of lipid peroxidation, increase of antioxidant capacity, cardamom active contents including phenols, polyphenols, minerals (Cu, Mn) [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>], 1,8-cineol [<xref ref-type="bibr" rid="CR92">92</xref>], and flavonoids [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par70">The observed effects of GC in NAFLD patients would make this study relevant. Although GC had been hypothetically used in the treatment of some disorders, it can be used in humans for further study in different diseases, particularly NAFLD. Also, the emerging rates of obesity and, consequently, NAFLD should be given more attention.</p><p id="Par71">This study has several strengths. First, the double-blinded stratified blocked randomization design; Second, the inclusion of patients with newly diagnosed NAFLD who had not yet received treatment; Third, considering multiple eligibility criteria; Fourth, protocol publication, Fifth, the determining of dietary intakes and physical activity status and adjusting the statistical analysis for them and other potential confounders; Sixth, considering control group. These strengths are likely preferable in comparison with few other clinical trials that have evaluated the effects of any spices on NAFLD patients.</p><p id="Par72">However, our study had some limitations. First, the sample size was small; Second, the intervention duration was short to understand the real effects of cardamom supplementation; Third, disregarding non-obese NAFLD patients. Fourth, self-reporting of diet and physical activity; Fifth, failure to perform liver biopsy and measure gamma-glutamyl transferase (GGT); Sixth, failure to check the bioavailability of GC and measure serum levels of its components; Seventh, 24-h food recall is not a good index for assessing the usual food intake; and Eighth, failure to measure body composition. Even so, this study is the first trial to evaluate the effects of GC on overweight/obese NAFLD patients.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par73">GC supplementation in obese NAFLD patients reduced inflammatory biomarkers (IL-6, TNF-&#x003b1;, and hs-CRP), ALT, and the degree of fatty liver and increased Sirt1 compared with placebo. Accordingly, GC may be useful in other metabolic diseases associated with inflammation. Further trials and considering the mentioned limitations are needed to confirm these results.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AOPP</term><def><p id="Par6">Advanced oxidation protein products</p></def></def-item><def-item><term>BMI</term><def><p id="Par7">Body mass index</p></def></def-item><def-item><term>CEO</term><def><p id="Par8">Cardamomum essential oil</p></def></def-item><def-item><term>COX-2</term><def><p id="Par9">Cyclooxygenase-2</p></def></def-item><def-item><term>ELISA</term><def><p id="Par10">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>GC</term><def><p id="Par11">Green cardamom</p></def></def-item><def-item><term>GC-MS</term><def><p id="Par12">Gas chromatography mass spectrometry</p></def></def-item><def-item><term>HPLC</term><def><p id="Par13">High-performance liquid chromatography</p></def></def-item><def-item><term>hs-CRP</term><def><p id="Par14">High-sensitivity C-reactive protein</p></def></def-item><def-item><term>IL-1&#x003b2;</term><def><p id="Par15">Interleukin-1 beta</p></def></def-item><def-item><term>IL-6</term><def><p id="Par16">Interleukin-6</p></def></def-item><def-item><term>iNOS</term><def><p id="Par17">Inducible-nitric oxide synthase</p></def></def-item><def-item><term>IPAQ</term><def><p id="Par18">International physical activity questionnaire</p></def></def-item><def-item><term>ITT</term><def><p id="Par19">Intention to treat</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par20">Non-alcoholic fatty liver disease</p></def></def-item><def-item><term>NASH</term><def><p id="Par21">Non-alcoholic steatohepatitis</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p id="Par22">Nuclear factor kappa-light-chain-enhancer of activated B cells</p></def></def-item><def-item><term>NIOC</term><def><p id="Par23">National Iranian Oil Company</p></def></def-item><def-item><term>PGC-1&#x003b1;</term><def><p id="Par24">PPAR-&#x003b3; co-activator-1 alpha</p></def></def-item><def-item><term>PPAR</term><def><p id="Par25">Peroxisome proliferation activated receptor</p></def></def-item><def-item><term>ROS</term><def><p id="Par26">Reactive oxygen species</p></def></def-item><def-item><term>Sirt-1</term><def><p id="Par27">Sirtuin-1</p></def></def-item><def-item><term>SOD</term><def><p id="Par28">Superoxide dismutase</p></def></def-item><def-item><term>TG</term><def><p id="Par29">Triglyceride</p></def></def-item><def-item><term>TMRC</term><def><p id="Par30">Traditional Medicine Research Center</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par31">Tumor necrosis factor-alpha</p></def></def-item><def-item><term>TPN</term><def><p id="Par32">Total parenteral nutrition</p></def></def-item><def-item><term>TWRM-ANOVA</term><def><p id="Par33">Two way repeated measures-analysis of covariance</p></def></def-item></def-list></glossary><ack><p>This research has been supported by Tehran University of Medical Sciences grant no. 94-03-161-30123. The cooperation of the NIOC central hospital of Tehran is acknowledged.</p><sec id="FPar1"><title>Availability of data and supporting materials</title><p id="Par74">Not applicable.</p></sec><sec id="FPar2"><title>Funding</title><p id="Par75">Funding was supported by the Tehran University of Medical Sciences (Code: 30123&#x02013;161&#x02013;03-94).</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MDM, GS, and SAK conceived and developed the idea for the paper and revised the manuscript. SM, SMA, MBF, and SAJT contributed to data collection. MBF wrote numerous drafts. MQ contributed to statistical interpretations. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>This trial was approved by the ethics committee of the Tehran University of Medical Sciences (Ethical Code: IR.TUMS.REC.1394.791). An informed consent form (in Persian) obtained from all the patients. Participation was free, and a patient could withdraw at whatever point the person feels he/she was unable to continue. The lifestyle advice was presented free to the patients and there was no bar to receiving the other health care services of the center. Side-effects of the supplements (up to 3&#x000a0;g/day) had not been reported previously. The personal information of patients was kept secret before, during, and after the study.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sherlock</surname><given-names>S</given-names></name><name><surname>Dooley</surname><given-names>J</given-names></name></person-group><source>Diseases of the Liver and Biliary System</source><year>2002</year><edition>11</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Blackwell Science</publisher-name><fpage>423</fpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibi</surname><given-names>A</given-names></name><name><surname>Jaberzadeh-Ansari</surname><given-names>M</given-names></name><name><surname>Dalili</surname><given-names>AR</given-names></name><name><surname>Omidifar</surname><given-names>N</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name></person-group><article-title>Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD) in Patients with Angina Pectoris</article-title><source>Open J Med Imag</source><year>2013</year><volume>3</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.4236/ojmi.2013.33015</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Koenig</surname><given-names>AB</given-names></name><name><surname>Abdelatif</surname><given-names>D</given-names></name><name><surname>Fazel</surname><given-names>Y</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Wymer</surname><given-names>M</given-names></name></person-group><article-title>Global epidemiology of nonalcoholic fatty liver disease&#x02014;Meta-analytic assessment of prevalence, incidence, and outcomes</article-title><source>Hepatology.</source><year>2016</year><volume>64</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/hep.28431</pub-id><?supplied-pmid 26707365?><pub-id pub-id-type="pmid">26707365</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbrini</surname><given-names>E</given-names></name><name><surname>Sh</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name></person-group><article-title>Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic and Clinical Implications</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><issue>2</issue><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1002/hep.23280</pub-id><?supplied-pmid 3575093?><pub-id pub-id-type="pmid">20041406</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioji</surname><given-names>K</given-names></name><name><surname>Sumida</surname><given-names>Y</given-names></name><name><surname>Kamaguchi</surname><given-names>M</given-names></name><name><surname>Mochizuki</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name></person-group><article-title>Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011&#x02013;2012</article-title><source>J Gastroenterol</source><year>2015</year><volume>50</volume><issue>1</issue><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1007/s00535-014-0948-9</pub-id><pub-id pub-id-type="pmid">24619537</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirkalali</surname><given-names>B</given-names></name><name><surname>Poustchi</surname><given-names>H</given-names></name><name><surname>Keyvani</surname><given-names>H</given-names></name><name><surname>Khansari</surname><given-names>MR</given-names></name><name><surname>Ajdarkosh</surname><given-names>H</given-names></name><name><surname>Maadi</surname><given-names>M</given-names></name><name><surname>Sohrabi</surname><given-names>MR</given-names></name><name><surname>Zamani</surname><given-names>F</given-names></name></person-group><article-title>Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran</article-title><source>Iranian J Public Health</source><year>2014</year><volume>43</volume><issue>9</issue><fpage>1275</fpage><lpage>1283</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri Lankarani</surname><given-names>K</given-names></name><name><surname>Ghaffarpasand</surname><given-names>F</given-names></name><name><surname>Mahmoodi</surname><given-names>M</given-names></name><name><surname>Lotfi</surname><given-names>M</given-names></name><name><surname>Zamiri</surname><given-names>N</given-names></name><name><surname>Heydari</surname><given-names>ST</given-names></name><name><surname>Fallahzadeh</surname><given-names>MK</given-names></name><name><surname>Maharlouei</surname><given-names>N</given-names></name><name><surname>Babaeinejad</surname><given-names>M</given-names></name><name><surname>Mehravar</surname><given-names>S</given-names></name><name><surname>Geramizadeh</surname><given-names>B</given-names></name></person-group><article-title>Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study</article-title><source>Hepat Mon</source><year>2013</year><volume>13</volume><issue>5</issue><fpage>e9248</fpage><pub-id pub-id-type="doi">10.5812/hepatmon.9248</pub-id><pub-id pub-id-type="pmid">23922564</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>Giovanni</given-names></name><name><surname>Molinaro</surname><given-names>Federica</given-names></name><name><surname>Paschetta</surname><given-names>Elena</given-names></name><name><surname>Gambino</surname><given-names>Roberto</given-names></name><name><surname>Cassader</surname><given-names>Maurizio</given-names></name></person-group><article-title>Lipid Modifiers and NASH: Statins, Ezetimibe, Fibrates, and Other Agents</article-title><source>Non-Alcoholic Fatty Liver Disease</source><year>2013</year><publisher-loc>Oxford, UK</publisher-loc><publisher-name>Wiley-Blackwell</publisher-name><fpage>293</fpage><lpage>307</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaharwar</surname><given-names>R</given-names></name><name><surname>Trikha</surname><given-names>S</given-names></name><name><surname>Margekar</surname><given-names>SL</given-names></name><name><surname>Jatav</surname><given-names>OP</given-names></name><name><surname>Ganga</surname><given-names>PD</given-names></name></person-group><article-title>Study of Clinical Profile of Patients of Non Alcoholic Fatty Liver Disease and its Association with Metabolic Syndrome</article-title><source>J Assoc Physicians India</source><year>2015</year><volume>63</volume><issue>1</issue><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">26591121</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Guideline Centre (UK)</collab></person-group><source>Non-Alcoholic Fatty Liver Disease: Assessment and Management</source><year>2016</year><publisher-loc>London</publisher-loc><publisher-name>National Institute for Health and Care Excellence (UK)</publisher-name></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>E.</given-names></name><name><surname>Carvalho</surname><given-names>D.</given-names></name><name><surname>Freitas</surname><given-names>P.</given-names></name></person-group><article-title>Gut Microbiota: Association with NAFLD and Metabolic Disturbances</article-title><source>BioMed Research International</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1155/2015/487372</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colak</surname><given-names>Y</given-names></name><name><surname>Ozturk</surname><given-names>O</given-names></name><name><surname>Senates</surname><given-names>E</given-names></name><name><surname>Tuncer</surname><given-names>I</given-names></name><name><surname>Yorulmaz</surname><given-names>E</given-names></name><name><surname>Adali</surname><given-names>G</given-names></name><name><surname>Doganay</surname><given-names>L</given-names></name><name><surname>Enc</surname><given-names>FY</given-names></name></person-group><article-title>SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease</article-title><source>Medical Sci Monit</source><year>2011</year><volume>17</volume><issue>5</issue><fpage>HY5</fpage><lpage>HY9</lpage><pub-id pub-id-type="doi">10.12659/MSM.881749</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><issue>2</issue><fpage>271</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i2.271</pub-id><?supplied-pmid 3020385?><pub-id pub-id-type="pmid">21246004</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>A</given-names></name></person-group><article-title>The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease</article-title><source>Clin Liver Dis</source><year>2004</year><volume>8</volume><issue>3</issue><fpage>521</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2004.04.004</pub-id><pub-id pub-id-type="pmid">15331061</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Caito</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Arunachalam</surname><given-names>G</given-names></name><name><surname>Rahman</surname><given-names>I</given-names></name></person-group><article-title>Regulation of SIRT1 in cellular functions: Role of polyphenols</article-title><source>Arch Biochem Biophys</source><year>2010</year><volume>501</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.05.003</pub-id><?supplied-pmid 2930135?><pub-id pub-id-type="pmid">20450879</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farris</surname><given-names>PK</given-names></name></person-group><article-title>Innovative Cosmeceuticals: Sirtuin Activators and Anti-Glycation Compounds</article-title><source>Semin Cutan Med Surg</source><year>2011</year><volume>30</volume><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.sder.2011.05.004</pub-id><pub-id pub-id-type="pmid">21925370</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salminena</surname><given-names>A</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name><name><surname>Kauppinenc</surname><given-names>A</given-names></name></person-group><article-title>Crosstalk between Oxidative Stress and SIRT1: Impact on the Aging Process</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>3834</fpage><lpage>3859</lpage><pub-id pub-id-type="doi">10.3390/ijms14023834</pub-id><pub-id pub-id-type="pmid">23434668</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>PJ</given-names></name><name><surname>Jirousek</surname><given-names>M</given-names></name></person-group><article-title>Sirtuins: Novel targets for metabolic disease</article-title><source>Curr Opin Investig Drugs</source><year>2008</year><volume>9</volume><issue>4</issue><fpage>371</fpage><lpage>378</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colak</surname><given-names>Y</given-names></name><name><surname>Yesil</surname><given-names>A</given-names></name><name><surname>Mutlu</surname><given-names>HH</given-names></name><name><surname>Caklili</surname><given-names>OT</given-names></name><name><surname>Ulasoglu</surname><given-names>C</given-names></name><name><surname>Senates</surname><given-names>E</given-names></name><name><surname>Takir</surname><given-names>M</given-names></name><name><surname>Kostek</surname><given-names>O</given-names></name><name><surname>Yilmaz</surname><given-names>Y</given-names></name><name><surname>Yilmaz Enc</surname><given-names>F</given-names></name><name><surname>Tasan</surname><given-names>G</given-names></name></person-group><article-title>A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators</article-title><source>J Gastrointestin Liver Dis</source><year>2014</year><volume>23</volume><issue>3</issue><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">25267960</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salminena</surname><given-names>A</given-names></name><name><surname>Kauppinenc</surname><given-names>A</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name></person-group><article-title>Phytochemicals suppress nuclear factor-kB signaling: impact on health span and the aging process</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2012</year><volume>15</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/MCO.0b013e32834d3ae7</pub-id><pub-id pub-id-type="pmid">22108095</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Fu</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Zhou</surname><given-names>XH</given-names></name></person-group><article-title>Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients</article-title><source>Ann Clin Lab Sci</source><year>2014</year><volume>44</volume><issue>4</issue><fpage>410</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">25361925</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name></person-group><article-title>Dietary Polyphenols and Their Biological Significance</article-title><source>Int J Mol Sci</source><year>2007</year><volume>8</volume><fpage>950</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.3390/i8090950</pub-id><?supplied-pmid 3871896?><pub-id pub-id-type="pmid">3871896</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brglez Mojzer</surname><given-names>E</given-names></name><name><surname>Knez Hrn&#x0010d;i&#x0010d;</surname><given-names>M</given-names></name><name><surname>&#x00160;kerget</surname><given-names>M</given-names></name><name><surname>Knez</surname><given-names>&#x0017d;</given-names></name><name><surname>Bren</surname><given-names>U</given-names></name></person-group><article-title>Polyphenols: Extraction methods, antioxidative action, bioavailability and anticarcinogenic effects</article-title><source>Molecules</source><year>2016</year><volume>21</volume><issue>7</issue><fpage>901</fpage><pub-id pub-id-type="doi">10.3390/molecules21070901</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Kang</surname><given-names>OH</given-names></name><name><surname>Choi</surname><given-names>YA</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Yun</surname><given-names>KJ</given-names></name><name><surname>Nah</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name></person-group><article-title>Inhibitory effect of luteolin on TNF-&#x003b1;-induced IL-8 production in human colon epithelial cells</article-title><source>International immunopharmacology</source><year>2005</year><volume>5</volume><issue>1</issue><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2004.09.027</pub-id><pub-id pub-id-type="pmid">15589482</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>Mari</given-names></name><name><surname>Nieminen</surname><given-names>Riina</given-names></name><name><surname>Vuorela</surname><given-names>Pia</given-names></name><name><surname>Heinonen</surname><given-names>Marina</given-names></name><name><surname>Moilanen</surname><given-names>Eeva</given-names></name></person-group><article-title>Anti-Inflammatory Effects of Flavonoids: Genistein, Kaempferol, Quercetin, and Daidzein Inhibit STAT-1 and NF-&#x003ba;B Activations, Whereas Flavone, Isorhamnetin, Naringenin, and Pelargonidin Inhibit only NF-&#x003ba;B Activation along with Their Inhibitory Effect on iNOS Expression and NO Production in Activated Macrophages</article-title><source>Mediators of Inflammation</source><year>2007</year><volume>2007</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2007/45673</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>HR</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Chung</surname><given-names>TS</given-names></name><name><surname>Chung</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name></person-group><article-title>Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rats gingival tissues</article-title><source>Biogerontology</source><year>2007</year><volume>8</volume><issue>4</issue><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1007/s10522-007-9083-9</pub-id><pub-id pub-id-type="pmid">17278014</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>JM</given-names></name><name><surname>Murphy</surname><given-names>EA</given-names></name><name><surname>Martin</surname><given-names>DC</given-names></name></person-group><article-title>Effects of the dietary flavonoid quercetin upon performance and health</article-title><source>Curr Sports Med Rep</source><year>2009</year><volume>8</volume><issue>4</issue><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1249/JSR.0b013e3181ae8959</pub-id><pub-id pub-id-type="pmid">19584608</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da-Silva</surname><given-names>WS</given-names></name><name><surname>Harney</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>BW</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Bianco</surname><given-names>SD</given-names></name><name><surname>Crescenzi</surname><given-names>A</given-names></name><name><surname>Christoffolete</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>SA</given-names></name><name><surname>Bianco</surname><given-names>AC</given-names></name></person-group><article-title>The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><issue>3</issue><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.2337/db06-1488</pub-id><pub-id pub-id-type="pmid">17327447</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Min-Jung</given-names></name><name><surname>Kim</surname><given-names>Dong-Il</given-names></name><name><surname>Choi</surname><given-names>Joo-Hee</given-names></name><name><surname>Heo</surname><given-names>Young-Ran</given-names></name><name><surname>Park</surname><given-names>Soo-Hyun</given-names></name></person-group><article-title>New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro</article-title><source>Cellular Signalling</source><year>2015</year><volume>27</volume><issue>9</issue><fpage>1831</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.04.010</pub-id><pub-id pub-id-type="pmid">25917316</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>JB</given-names></name><name><surname>Bhathal</surname><given-names>PS</given-names></name><name><surname>Hughes</surname><given-names>NR</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>PE</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><fpage>1647</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1002/hep.20251</pub-id><pub-id pub-id-type="pmid">15185306</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Stufflebam</surname><given-names>A</given-names></name><name><surname>Hilton</surname><given-names>TN</given-names></name><name><surname>Sinacore</surname><given-names>DR</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Villareal</surname><given-names>DT</given-names></name></person-group><article-title>Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults</article-title><source>Obesity.</source><year>2009</year><volume>17</volume><fpage>2162</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1038/oby.2009.126</pub-id><pub-id pub-id-type="pmid">19390517</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Yang</surname><given-names>QH</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>YJ</given-names></name><name><surname>He</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Zhang</surname><given-names>JW</given-names></name></person-group><article-title>Effects of Berberine on Hepatic Sirtuin 1-uncoupling Protein 2 Pathway in Non-alcoholic Fatty Liver Disease Rats Induced by High-fat Diet</article-title><source>Chinese Herbal Med.</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S1674-6384(16)60063-1</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Weight-loss diets for the prevention and treatment of obesity</article-title><source>N Engl J Med.</source><year>2009</year><volume>360</volume><fpage>923</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1056/NEJMe0810291</pub-id><pub-id pub-id-type="pmid">19246365</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelber-Sagi</surname><given-names>S</given-names></name><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name></person-group><article-title>Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence</article-title><source>World J Gastroenterol.</source><year>2011</year><volume>17</volume><issue>29</issue><fpage>3377</fpage><lpage>3389</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i29.3377</pub-id><?supplied-pmid 3160564?><pub-id pub-id-type="pmid">21876630</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneshi-Maskooni</surname><given-names>M</given-names></name><name><surname>Keshavarz</surname><given-names>SA</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Badri-Fariman</surname><given-names>M</given-names></name><name><surname>Jazayeri-Tehrani</surname><given-names>SA</given-names></name><name><surname>Sotoudeh</surname><given-names>G</given-names></name></person-group><article-title>The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial</article-title><source>Trials.</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>260</fpage><pub-id pub-id-type="doi">10.1186/s13063-017-1979-3</pub-id><?supplied-pmid 5463368?><pub-id pub-id-type="pmid">28592311</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jazayeri-Tehrani</surname><given-names>SA</given-names></name><name><surname>Rezayat</surname><given-names>SM</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Daneshi-Maskooni</surname><given-names>M</given-names></name><name><surname>Hosseinzadeh-Attar</surname><given-names>MJ</given-names></name></person-group><article-title>Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol</article-title><source>BMJ open.</source><year>2017</year><volume>7</volume><issue>7</issue><fpage>e016914</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-016914</pub-id><?supplied-pmid 5726126?><pub-id pub-id-type="pmid">5726126</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jazayeri-Tehrani</surname><given-names>SA</given-names></name><name><surname>Rezayat</surname><given-names>SM</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Daneshi-Maskooni</surname><given-names>M</given-names></name><name><surname>Hosseinzadeh-Attar</surname><given-names>MJ</given-names></name></person-group><article-title>The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial</article-title><source>Nanomed J</source><year>2018</year><volume>5</volume><issue>2</issue><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.22038/nmj.10.22038/nmj.2018.005.002</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>SK</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name><name><surname>Katewa</surname><given-names>SS</given-names></name></person-group><article-title>Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of Cardamom (<italic>Elettaria cardamomum</italic>)</article-title><source>Indian J Biochem Biophys</source><year>2009</year><volume>46</volume><fpage>503</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">20361714</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Vijayan KK, Madhusoodanan KJ, Radhakrishnan VV, Ravindran PN. Chapter 12: Properties and end-uses of cardamom, Cardamom The genus Elettaria. Book. Abingdon-on-Thames: Taylor &#x00026; Francis; 2002.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suneetha</surname><given-names>WJ</given-names></name><name><surname>Krishnakantha</surname><given-names>TP</given-names></name></person-group><article-title>Cardamom Extract as Inhibitor of Human Platelet Aggregation</article-title><source>Phytother Res</source><year>2005</year><volume>19</volume><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/ptr.1681</pub-id><pub-id pub-id-type="pmid">16106388</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>Archana</given-names></name><name><surname>Bhattacharjee</surname><given-names>Shamee</given-names></name></person-group><article-title>Cardamom (Elettaria cardamomum) and Its Active Constituent, I,8-cineole</article-title><source>Molecular Targets and Therapeutic Uses of Spices</source><year>2009</year><fpage>65</fpage><lpage>85</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Campo</surname><given-names>JA</given-names></name><name><surname>Gallego-Dur&#x000e1;n</surname><given-names>R</given-names></name><name><surname>Gallego</surname><given-names>P</given-names></name><name><surname>Grande</surname><given-names>L</given-names></name></person-group><article-title>Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>3</issue><fpage>911</fpage><pub-id pub-id-type="doi">10.3390/ijms19030911</pub-id><?supplied-pmid 5877772?><pub-id pub-id-type="pmid">5877772</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>RB</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><article-title>Emerging roles of SIRT1 in fatty liver diseases</article-title><source>Int J Biol Sci</source><year>2017</year><volume>13</volume><issue>7</issue><fpage>852</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.7150/ijbs.19370</pub-id><?supplied-pmid 5555103?><pub-id pub-id-type="pmid">28808418</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>SK</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>DP</given-names></name></person-group><article-title>Effect of Greater cardamom (Amomum subulatum Roxb.) on blood lipids, fibrinolysis and total antioxidant status in patients with ischemic heart disease</article-title><source>Asian Pac J Trop Dis</source><year>2012</year><volume>2</volume><fpage>S739</fpage><lpage>S743</lpage><pub-id pub-id-type="doi">10.1016/S2222-1808(12)60255-2</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekhlasi</surname><given-names>G</given-names></name><name><surname>Shidfar</surname><given-names>F</given-names></name><name><surname>Agah</surname><given-names>S</given-names></name><name><surname>Merat</surname><given-names>S</given-names></name><name><surname>Hosseini</surname><given-names>KAF</given-names></name></person-group><article-title>Effect of pomegranate juice intake on lipid profile in patients with nonalcoholic fatty liver disease</article-title><source>Razi J Med Sci</source><year>2013</year><volume>20</volume><issue>111</issue><fpage>30</fpage><lpage>39</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name><name><surname>Pagano</surname><given-names>G</given-names></name></person-group><article-title>A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease</article-title><source>Hepatology.</source><year>2010</year><volume>52</volume><fpage>79</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1002/hep.23623</pub-id><pub-id pub-id-type="pmid">20578268</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jazayeri</surname><given-names>S</given-names></name><name><surname>Nouri</surname><given-names>M</given-names></name><name><surname>Pour-Ebrahim</surname><given-names>R</given-names></name><name><surname>Fakhrzadeh</surname><given-names>H</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name></person-group><article-title>Food and nutrient intake status in urban population (20&#x02013;60 years) of population research center of Tehran University of Medical Sciences</article-title><source>Iran J Diab Lipid</source><year>2005</year><volume>1</volume><issue>3</issue><fpage>81</fpage><lpage>89</lpage></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Qaffarpour</surname><given-names>M</given-names></name><name><surname>Houshyar-Rad</surname><given-names>A</given-names></name><name><surname>Kianfar</surname><given-names>H</given-names></name></person-group><source>Guides of home scales, conversion coefficients and percentage of Iranian foods</source><year>2000</year><publisher-loc>Tehran</publisher-loc><publisher-name>Agricultural Sciences Publication</publisher-name></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>The IPAQ group</collab></person-group><source>International physical activity questionnaire [Internet]</source><year>2017</year></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vafai-Najar</surname><given-names>A</given-names></name><name><surname>Vahedian-Shahroodi</surname><given-names>M</given-names></name><name><surname>Tehrani</surname><given-names>H</given-names></name><name><surname>Dogonchi</surname><given-names>M</given-names></name><name><surname>Lael-Monfared</surname><given-names>E</given-names></name></person-group><article-title>The effectiveness of physical activity training on depersonalization of employees</article-title><source>Iran J Health Educ Health Promot. Summer</source><year>2015</year><volume>3</volume><issue>2</issue><fpage>116</fpage><lpage>124</lpage></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baghiani-Moghaddam</surname><given-names>MH</given-names></name><name><surname>Bakhtiari-Aghdam</surname><given-names>F</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Allahverdipour</surname><given-names>H</given-names></name><name><surname>Saeed Dabagh-Nikookheslat</surname><given-names>S</given-names></name><name><surname>Nourizadeh</surname><given-names>R</given-names></name></person-group><article-title>Comparing the Results of Pedometer-Based Data and International Physical Activity Questionnaire (IPAQ)</article-title><source>J Health Syst Res</source><year>2013</year><volume>9</volume><issue>6</issue><fpage>605</fpage><lpage>612</lpage></element-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">The lab tests online. Laboratory Methods Used For Medical Lab Testing (Enzyme-linked immunosorbent assay (ELISA)) [Internet]. 2012 [cited 26 Feb 2017]. Available from: <ext-link ext-link-type="uri" xlink:href="https://labtestsonline.org/understanding/features/methods/start/2/">https://labtestsonline.org/understanding/features/methods/start/2/</ext-link>.</mixed-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajami</surname><given-names>M</given-names></name><name><surname>Pazoki-Toroudi</surname><given-names>H</given-names></name><name><surname>Amani</surname><given-names>H</given-names></name><name><surname>Nabavi</surname><given-names>SF</given-names></name><name><surname>Braidy</surname><given-names>N</given-names></name><name><surname>Vacca</surname><given-names>RA</given-names></name><name><surname>Atanasov</surname><given-names>AG</given-names></name><name><surname>Mocan</surname><given-names>A</given-names></name><name><surname>Nabavi</surname><given-names>SM</given-names></name></person-group><article-title>Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols</article-title><source>Neurosc Biobehav Rev.</source><year>2017</year><volume>73</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.11.022</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>AY</given-names></name><name><surname>Motechin</surname><given-names>RA</given-names></name><name><surname>Wiesenfeld</surname><given-names>MY</given-names></name><name><surname>Holz</surname><given-names>MK</given-names></name></person-group><article-title>The therapeutic potential of resveratrol: a review of clinical trials</article-title><source>NPJ Precision Oncol</source><year>2017</year><volume>1</volume><issue>1</issue><fpage>35</fpage><pub-id pub-id-type="doi">10.1038/s41698-017-0038-6</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>GS</given-names></name></person-group><article-title>A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2</article-title><source>Altern Med Rev.</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>313</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">21194247</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>DA</given-names></name><name><surname>Mariana Ap</surname><given-names>BR</given-names></name><name><surname>Papadimitriou</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>KC</given-names></name><name><surname>Amancio</surname><given-names>VH</given-names></name><name><surname>Mendon&#x000e7;a</surname><given-names>JN</given-names></name><name><surname>Lopes</surname><given-names>NP</given-names></name><name><surname>de Faria</surname><given-names>JB</given-names></name><name><surname>de Faria</surname><given-names>JM</given-names></name></person-group><article-title>Polyphenol-enriched cocoa protects the diabetic retina from glial reaction through the sirtuin pathway</article-title><source>J Nutr Biochem.</source><year>2015</year><volume>26</volume><issue>1</issue><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2014.09.003</pub-id><pub-id pub-id-type="pmid">25448608</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>S</given-names></name><name><surname>Papaioannou</surname><given-names>AI</given-names></name><name><surname>Papaporfyriou</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>JR</given-names></name><name><surname>Vuppusetty</surname><given-names>C</given-names></name><name><surname>Loukides</surname><given-names>S</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name></person-group><article-title>Decreased serum sirtuin-1 in COPD</article-title><source>Chest</source><year>2017</year><volume>152</volume><issue>2</issue><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2017.05.004</pub-id><?supplied-pmid 5540026?><pub-id pub-id-type="pmid">28506610</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bo</surname><given-names>S</given-names></name><name><surname>Togliatto</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Ponzo</surname><given-names>V</given-names></name><name><surname>Lombardo</surname><given-names>G</given-names></name><name><surname>Rosato</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name><name><surname>Brizzi</surname><given-names>MF</given-names></name></person-group><article-title>Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation</article-title><source>Acta diabetologica</source><year>2018</year><volume>55</volume><issue>4</issue><fpage>331</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s00592-017-1097-4</pub-id><?supplied-pmid 5851693?><pub-id pub-id-type="pmid">29330620</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboelnaga</surname><given-names>SM</given-names></name></person-group><article-title>Effect of some levels of cardamom, clove and anise on hepatotoxicity in rats caused by CCL4</article-title><source>World Appl Sci J</source><year>2015</year><volume>33</volume><issue>6</issue><fpage>854</fpage><lpage>865</lpage></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>MM</given-names></name><name><surname>Alam</surname><given-names>MN</given-names></name><name><surname>Ulla</surname><given-names>A</given-names></name><name><surname>Sumi</surname><given-names>FA</given-names></name><name><surname>Subhan</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Sikder</surname><given-names>B</given-names></name><name><surname>Hossain</surname><given-names>H</given-names></name><name><surname>Reza</surname><given-names>HM</given-names></name><name><surname>Alam</surname><given-names>MA</given-names></name></person-group><article-title>Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats</article-title><source>Lipids Health Dis</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.1186/s12944-017-0539-x</pub-id><?supplied-pmid 5557534?><pub-id pub-id-type="pmid">28806968</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azimi</surname><given-names>P</given-names></name><name><surname>Ghiasvand</surname><given-names>R</given-names></name><name><surname>Feizi</surname><given-names>A</given-names></name><name><surname>Hariri</surname><given-names>M</given-names></name><name><surname>Abbasi</surname><given-names>B</given-names></name></person-group><article-title>Effects of cinnamon, cardamom, saffron, and ginger consumption on markers of glycemic control, lipid profile, oxidative stress, and inflammation in type 2 diabetes patients</article-title><source>Rev Diabet Stud</source><year>2014</year><volume>11</volume><issue>3</issue><fpage>258</fpage><pub-id pub-id-type="doi">10.1900/RDS.2014.11.258</pub-id><pub-id pub-id-type="pmid">26177486</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>A</given-names></name><name><surname>Rathod</surname><given-names>M</given-names></name></person-group><article-title>An in vitro study of the immunomodulatory effects of <italic>Piper nigrum</italic> (black pepper) and <italic>Elettaria cardamomum</italic> (cardamom) extracts using a murine macrophage cell line</article-title><source>AIJRFANS</source><year>2014</year><volume>8</volume><fpage>18</fpage><lpage>27</lpage></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majdalawieh</surname><given-names>AF</given-names></name><name><surname>Carr</surname><given-names>RI</given-names></name></person-group><article-title>In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (<italic>Piper nigrum</italic>) and cardamom (<italic>Elettaria cardamomum</italic>)</article-title><source>J Med Food.</source><year>2010</year><volume>13</volume><issue>2</issue><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1089/jmf.2009.1131</pub-id><pub-id pub-id-type="pmid">20210607</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radomska-Le&#x0015b;niewska</surname><given-names>DM</given-names></name><name><surname>Skopi&#x00144;ski</surname><given-names>P</given-names></name><name><surname>Niemcewicz</surname><given-names>M</given-names></name><name><surname>Zdanowski</surname><given-names>R</given-names></name><name><surname>Lewicki</surname><given-names>S</given-names></name><name><surname>Kocik</surname><given-names>J</given-names></name><name><surname>Skopi&#x00144;ska-R&#x000f3;&#x0017c;ewska</surname><given-names>E</given-names></name><name><surname>Stankiewicz</surname><given-names>W</given-names></name></person-group><article-title>The effect of anti-inflammatory and antimicrobial herbal remedy PADMA 28 on immunological angiogenesis and granulocytes activity in mice</article-title><source>Mediators Inflamm.</source><year>2013</year><volume>2013</volume><fpage>853475</fpage><pub-id pub-id-type="doi">10.1155/2013/853475</pub-id><?supplied-pmid 3707257?><pub-id pub-id-type="pmid">23864768</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandikattu</surname><given-names>HK</given-names></name><name><surname>Rachitha</surname><given-names>P</given-names></name><name><surname>Jayashree</surname><given-names>GV</given-names></name><name><surname>Krupashree</surname><given-names>K</given-names></name><name><surname>Sukhith</surname><given-names>M</given-names></name><name><surname>Majid</surname><given-names>A</given-names></name><name><surname>Amruta</surname><given-names>N</given-names></name><name><surname>Khanum</surname><given-names>F</given-names></name></person-group><article-title>Anti-inflammatory and anti-oxidant effects of Cardamom (Elettaria repens (Sonn.) Baill) and its phytochemical analysis by 4D GCXGC TOF-MS</article-title><source>Biomed Pharmacother.</source><year>2017</year><volume>91</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.04.049</pub-id><pub-id pub-id-type="pmid">28458157</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elguindy</surname><given-names>NM</given-names></name><name><surname>Yacout</surname><given-names>GA</given-names></name><name><surname>El Azab</surname><given-names>EF</given-names></name><name><surname>Maghraby</surname><given-names>HK</given-names></name></person-group><article-title>Chemoprotective Effect of <italic>Elettaria cardamomum</italic> against Chemically induced Hepatocellular Carcinoma in Rats by Inhibiting NF-&#x003ba;B, Oxidative Stress, and Activity of Ornithine Decarboxylase</article-title><source>S Afr J Bot</source><year>2016</year><volume>105</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.sajb.2016.04.001</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darwish</surname><given-names>MM</given-names></name><name><surname>Ash</surname><given-names>AEA</given-names></name></person-group><article-title>Role of cardamom (<italic>Elettaria cardamomum</italic>) in ameliorating radiation induced oxidative stress in rats</article-title><source>Arab J Nucl Sci Appl</source><year>2013</year><volume>46</volume><issue>1</issue><fpage>232</fpage><lpage>239</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asimi</surname><given-names>OA</given-names></name><name><surname>Sahu</surname><given-names>NP</given-names></name></person-group><article-title>Effect of Antioxidant Rich Spices, Clove and Cardamom Extracts on the Metabolic Enzyme Activity of <italic>Labeo rohita</italic></article-title><source>J Fish Livest Prod.</source><year>2016</year><volume>1</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboubakr</surname><given-names>M</given-names></name><name><surname>Abdelazem</surname><given-names>AM</given-names></name></person-group><article-title>Hepatoprotective effect of aqueous extract cardamom against gentamicin induced hepatic damage in rats</article-title><source>Int J Basic Appl Sci.</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>1</fpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghane</surname><given-names>Z</given-names></name><name><surname>Vazini</surname><given-names>H</given-names></name><name><surname>Pirestani</surname><given-names>M</given-names></name></person-group><article-title>Protective Effect of Hydroalcoholic Extract of <italic>Elettaria cardamomum</italic> L. Fruits on Serum Levels of Liver Enzymes and Morphpological Changes in Lead Induced Male Rats</article-title><source>J Mazandaran Univ Med Sci.</source><year>2016</year><volume>26</volume><issue>142</issue><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaswant</surname><given-names>M</given-names></name><name><surname>Poudyal</surname><given-names>H</given-names></name><name><surname>Mathai</surname><given-names>ML</given-names></name><name><surname>Ward</surname><given-names>LC</given-names></name><name><surname>Mouatt</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name></person-group><article-title>Green and black cardamom in a diet-induced rat model of metabolic syndrome</article-title><source>Nutrients.</source><year>2015</year><volume>7</volume><issue>9</issue><fpage>7691</fpage><lpage>7707</lpage><pub-id pub-id-type="doi">10.3390/nu7095360</pub-id><?supplied-pmid 4586555?><pub-id pub-id-type="pmid">26378573</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname><given-names>S</given-names></name><name><surname>Yaghooblou</surname><given-names>F</given-names></name><name><surname>Siassi</surname><given-names>F</given-names></name><name><surname>Rahimi</surname><given-names>AF</given-names></name><name><surname>Ghavipour</surname><given-names>M</given-names></name><name><surname>Koohdani</surname><given-names>F</given-names></name><name><surname>Sotoudeh</surname><given-names>G</given-names></name></person-group><article-title>Cardamom supplementation improves inflammatory and oxidative stress biomarkers in hyperlipidemic, overweight, and obese pre-diabetic women: a randomized double-blind clinical trial</article-title><source>J Sci Food Agric.</source><year>2017</year><volume>97</volume><issue>15</issue><fpage>5296</fpage><lpage>5301</lpage><pub-id pub-id-type="doi">10.1002/jsfa.8414</pub-id><pub-id pub-id-type="pmid">28480505</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badkook</surname><given-names>MM</given-names></name><name><surname>Shrourou</surname><given-names>RM</given-names></name></person-group><article-title>Arabic coffee with two doses of cardamom: effects on health biomarkers in healthy women</article-title><source>Int J Nutr Food Sci</source><year>2013</year><volume>2</volume><issue>6</issue><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.11648/j.ijnfs.20130206.13</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>J</given-names></name></person-group><article-title>Identification of proapoptopic, anti-inflammatory, anti-proliferative, anti-invasive and anti-angiogenic targets of essential oils in cardamom by dual reverse virtual screening and binding pose analysis</article-title><source>Asian Pac J Cancer Prev</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>3735</fpage><lpage>3742</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2013.14.6.3735</pub-id><pub-id pub-id-type="pmid">23886174</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>Md. Asiful</given-names></name><name><surname>Alam</surname><given-names>Fahmida</given-names></name><name><surname>Solayman</surname><given-names>Md.</given-names></name><name><surname>Khalil</surname><given-names>Md. Ibrahim</given-names></name><name><surname>Kamal</surname><given-names>Mohammad Amjad</given-names></name><name><surname>Gan</surname><given-names>Siew Hua</given-names></name></person-group><article-title>Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases</article-title><source>Oxidative Medicine and Cellular Longevity</source><year>2016</year><volume>2016</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1155/2016/5137431</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yashin</surname><given-names>A</given-names></name><name><surname>Yashin</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Nemzer</surname><given-names>B</given-names></name></person-group><article-title>Antioxidant activity of spices and their impact on human health: A Review</article-title><source>Antioxidants.</source><year>2017</year><volume>6</volume><issue>3</issue><fpage>70</fpage><pub-id pub-id-type="doi">10.3390/antiox6030070</pub-id><?supplied-pmid 5618098?><pub-id pub-id-type="pmid">5618098</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>E</given-names></name></person-group><article-title>Molecular signaling mechanisms behind polyphenol-induced bone anabolism</article-title><source>Phytochem Rev</source><year>2017</year><volume>16</volume><issue>6</issue><fpage>1183</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1007/s11101-017-9529-x</pub-id><?supplied-pmid 5696504?><pub-id pub-id-type="pmid">29200988</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suen</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Kranz</surname><given-names>A</given-names></name><name><surname>Vun</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name></person-group><article-title>Effect of Flavonoids on Oxidative Stress and Inflammation in Adults at Risk of Cardiovascular Disease: A Systematic Review</article-title><source>Healthcare (Basel, Switzerland)</source><year>2016</year><volume>4</volume><issue>3</issue><fpage>69</fpage><pub-id pub-id-type="doi">10.3390/healthcare4030069</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>R</given-names></name><name><surname>Ballester</surname><given-names>I</given-names></name><name><surname>L&#x000f3;pez-Posadas</surname><given-names>R</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>MD</given-names></name><name><surname>Zarzuelo</surname><given-names>A</given-names></name><name><surname>Martinez-Augustin</surname><given-names>O</given-names></name><name><surname>Medina</surname><given-names>FS</given-names></name></person-group><article-title>Effects of flavonoids and other polyphenols on inflammation</article-title><source>Crit Rev Food Sci Nutr</source><year>2011</year><volume>51</volume><issue>4</issue><fpage>331</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1080/10408390903584094</pub-id><pub-id pub-id-type="pmid">21432698</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>Tarique</given-names></name><name><surname>Tan</surname><given-names>Bie</given-names></name><name><surname>Yin</surname><given-names>Yulong</given-names></name><name><surname>Blachier</surname><given-names>Francois</given-names></name><name><surname>Tossou</surname><given-names>Myrlene C. B.</given-names></name><name><surname>Rahu</surname><given-names>Najma</given-names></name></person-group><article-title>Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?</article-title><source>Oxidative Medicine and Cellular Longevity</source><year>2016</year><volume>2016</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1155/2016/7432797</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsume</surname><given-names>M</given-names></name></person-group><article-title>Polyphenols: inflammation</article-title><source>Curr Pharm Des.</source><year>2017</year><volume>24</volume><issue>2</issue><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2174/1381612823666171109104141</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyay</surname><given-names>Swapna</given-names></name><name><surname>Dixit</surname><given-names>Madhulika</given-names></name></person-group><article-title>Role of Polyphenols and Other Phytochemicals on Molecular Signaling</article-title><source>Oxidative Medicine and Cellular Longevity</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1155/2015/504253</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>PW</given-names></name></person-group><article-title>Inhibitory effects of several spices on inflammation caused by advanced glycation endproducts</article-title><source>Am J Plant Sci.</source><year>2012</year><volume>3</volume><issue>07</issue><fpage>995</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.4236/ajps.2012.327118</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>KB</given-names></name><name><surname>Rizvi</surname><given-names>SI</given-names></name></person-group><article-title>Current understanding of dietary polyphenols and their role in health and disease</article-title><source>Curr Nutr Food Sci</source><year>2009</year><volume>5</volume><issue>4</issue><fpage>249</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.2174/157340109790218058</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winarsi</surname><given-names>H</given-names></name><name><surname>Yuniaty</surname><given-names>A</given-names></name><name><surname>Nuraeni</surname><given-names>I</given-names></name></person-group><article-title>Improvement of Antioxidant and Immune Status of Atherosclerotic Rats Adrenaline and Egg-Yolks-Induced Using Cardamom-Rhizome-Ethanolic-Extract: An Initial Study of Functional Food</article-title><source>Agric Agric Sci Procedia</source><year>2016</year><volume>9</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.aaspro.2016.02.147</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name><name><surname>Van Kuiken</surname><given-names>ME</given-names></name><name><surname>Iyer</surname><given-names>LH</given-names></name><name><surname>Harikumar</surname><given-names>KB</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name></person-group><article-title>Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis</article-title><source>Exp Biol Med.</source><year>2009</year><volume>234</volume><issue>8</issue><fpage>825</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.3181/0902-MR-78</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>I</given-names></name><name><surname>Acharya</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>DL</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Permaul</surname><given-names>E</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>T</given-names></name></person-group><article-title>Antioxidative effects of the spice cardamom against non-melanoma skin cancer by modulating nuclear factor erythroid-2-related factor 2 and NF-&#x003ba;B signalling pathways</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><issue>6</issue><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1017/S0007114511006283</pub-id><pub-id pub-id-type="pmid">22182368</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Parker</surname><given-names>TL</given-names></name></person-group><article-title>Cardamom (<italic>Elettaria cardamomum</italic>) essential oil significantly inhibits vascular cell adhesion molecule 1 and impacts genome-wide gene expression in human dermal fibroblasts</article-title><source>Cogent Med</source><year>2017</year><volume>4</volume><issue>1</issue><fpage>1308066</fpage></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Othman</surname><given-names>AM</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Al-Orf</surname><given-names>S</given-names></name><name><surname>Al-Murshed</surname><given-names>KS</given-names></name><name><surname>Arif</surname><given-names>Z</given-names></name></person-group><article-title>Effect of dietary supplementation of Ellataria cardamomum and <italic>Nigella sativa</italic> on the toxicity of rancid corn oil in Rats</article-title><source>Int J Pharmacol</source><year>2006</year><volume>2</volume><issue>1</issue><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.3923/ijp.2006.60.65</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeek</surname><given-names>EA</given-names></name><name><surname>El-Razek</surname><given-names>FH</given-names></name></person-group><article-title>The chemo-protective effect of turmeric, chili, cloves and cardamom on correcting iron overload-induced liver injury, oxidative stress and serum lipid profile in rat models</article-title><source>J Am Sci</source><year>2010</year><volume>6</volume><issue>10</issue><fpage>7</fpage></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>GN</given-names></name><name><surname>Nayak</surname><given-names>N</given-names></name><name><surname>Vinodraj</surname><given-names>K</given-names></name><name><surname>Chandralekha</surname><given-names>N</given-names></name><name><surname>Mathai</surname><given-names>P</given-names></name><name><surname>Cherian</surname><given-names>J</given-names></name></person-group><article-title>Comparison of the efficacy of cardamom (<italic>Elettaria cardamomum</italic>) with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in albino rats</article-title><source>J Adv Pharm Technol Res</source><year>2015</year><volume>6</volume><issue>3</issue><fpage>136</fpage><pub-id pub-id-type="doi">10.4103/2231-4040.157981</pub-id><pub-id pub-id-type="pmid">26317079</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamzaa</surname><given-names>RG</given-names></name><name><surname>Osman</surname><given-names>NN</given-names></name></person-group><article-title>Using of coffee and cardamom mixture to ameliorate oxidative stress induced in &#x003b3;-irradiated rats</article-title><source>Biochem Anal Biochem</source><year>2012</year><volume>1</volume><issue>113</issue><fpage>2161</fpage><lpage>1009</lpage></element-citation></ref></ref-list></back></article>